These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33624108)

  • 1. Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter?
    Cavallari I; Maddaloni E; Grigioni F
    Eur J Prev Cardiol; 2021 Dec; 28(15):1670-1672. PubMed ID: 33624108
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
    Patoulias D; Papadopoulos C; Doumas M
    Am Heart J; 2021 Jun; 236():104-105. PubMed ID: 33902820
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
    Buonacera A; Stancanelli B; Malatino L
    High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):331-332. PubMed ID: 33905096
    [No Abstract]   [Full Text] [Related]  

  • 5. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
    Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
    Wu K; Zhao S
    Circulation; 2020 Jul; 142(1):e3-e4. PubMed ID: 32628545
    [No Abstract]   [Full Text] [Related]  

  • 9. Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
    Jackson AM; Jhund PS; Solomon SD; McMurray JJV
    Circulation; 2020 Jul; 142(1):e5-e6. PubMed ID: 32628550
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV
    JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure features and sacubitril/valsartan effects.
    Malfatto G; Villani A; Parati G
    J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):234-235. PubMed ID: 33136813
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients.
    Rerick L; Elston C; Kester J; Montepara C; Gengler B
    J Cardiovasc Pharmacol; 2021 Mar; 77(3):343-348. PubMed ID: 33298737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
    Huang Y; Zhang Y; Ma L; Zhou H; Fang C; Chen C
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):202-210. PubMed ID: 33929386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?
    Gallo G; Rubattu S; Volpe M
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):541-545. PubMed ID: 34750764
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis.
    Teo YN; Teo YH; Syn NL; Yoong CSY; Cheong AJY; Wee CF; Lim YC; Lee CH; Yeo TC; Chai P; Wong RCC; Lin W; Sia CH
    Clin Drug Investig; 2022 Jan; 42(1):1-16. PubMed ID: 34797518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cause and duration of heart failure may impact on the response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
    Mandal AKJ; Missouris CG
    J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):233-234. PubMed ID: 32925393
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Ollendorf DA; Chapman RH; Pearson SD; Heidenreich PA
    Ann Intern Med; 2016 Nov; 165(10):681-689. PubMed ID: 27571284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
    Mirić D; Baković D; Eterović D; Sorić T; Čapkun V; Vuković I; Duplančić D; Barac A
    J Cardiovasc Transl Res; 2021 Apr; 14(2):290-298. PubMed ID: 32557158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Sacubitril/Valsartan on Right Heart Failure.
    Imamura T; Hori M; Ueno H; Kinugawa K
    Int Heart J; 2021 Jul; 62(4):932-934. PubMed ID: 34276024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of sacubitril/valsartan among older adults. Where real world data meet clinical trials results.
    Garcia-Moll X; Lopez L
    Int J Cardiol; 2024 Apr; 400():131706. PubMed ID: 38168560
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.